Metastatic Hepatocellular Carcinoma (HCC) is an indication for drug development with over 110 pipeline drugs currently active. According to GlobalData, preregistered drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Metastatic Hepatocellular Carcinoma (HCC) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Metastatic Hepatocellular Carcinoma (HCC) overview
Metastatic hepatocellular carcinoma (HCC) refers to liver cancer that has spread to other parts of the body. It originates in liver cells and often spreads to the lungs, bones, lymph nodes, or other organs. Symptoms at this stage can include jaundice, abdominal pain, weight loss, and fatigue. Treatment options for metastatic HCC involve a combination of therapies, such as targeted drug treatments, immunotherapy, chemotherapy, radiation, and sometimes surgical interventions or liver-directed therapies. Prognosis for metastatic HCC tends to be challenging due to its aggressive nature, but personalized treatment plans and supportive care can improve quality of life and extend survival rates. Regular monitoring is crucial to assess the progression and response to treatment.
For a complete picture of PTSR and LoA scores for drugs in Metastatic Hepatocellular Carcinoma (HCC), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
